On February 19, 2026, Japanese government experts approved significant projects aimed at creating regenerative medicine products intended to treat heart diseases and Parkinson's disease. This endorsement marks a groundbreaking achievement in the field of regenerative medicine, as the products now await final approval from the Health Ministry. The developments are particularly notable as they could lead to the world's first commercially available medical products utilizing induced Pluripotent Stem (iPS) cells, renowned for their ability to become any type of cell in the human body. The proposals include innovative treatments such as ReHeart, which consists of heart muscle sheets developed by the medical startup Cuorips. These sheets are designed to help regenerate heart tissue by forming new blood vessels, ultimately aiming to restore heart function in affected patients. Additionally, other projects, including one by Sumitomo Pharma and Racthera, focus on providing new solutions for patients suffering from Parkinson's disease. The significant advancements in the use of iPS cells are grounded in the pioneering research conducted by Japanese scientist Shinya Yamanaka, who was awarded the Nobel Prize in 2012 for his work in this area. His discovery has paved the way for the practical application of iPS cells, which can be derived from already specialized cells without the need for an embryo, allowing cloning-like capabilities that could revolutionize regenerative medicine. Following the panel's endorsement, Yamanaka expressed optimism and emphasized that further efforts are needed to support patients who are in dire need of these innovative treatments. If the Health Ministry grants final approval, these advancements may transform how we address prevalent conditions such as heart disease and Parkinson's disease, offering hope for improved outcomes and quality of life for many patients. The approval process by the Health Ministry remains a crucial step that will determine the future availability of these groundbreaking medical products, which are set to lead the way in regenerative medicine worldwide.